Guselkumab, anti-IL23 in PsA Ph3 DISCOVER-1 trial in bio-naive or 30% prior TNFi = Effective at Wk 24 Safety same as with psoriasis trials. No Tb signal, No IBD signal. #ACR19 Abst0807 @_connectedcare https://t.co/d7hrn8VQO8